Targeting tyrosine-protein kinase Lck (LCK) with dasatinib has demonstrated activity against T-cell acute lymphoblastic leukemia (T-ALL). To make the effects more lasting, researchers from St. Jude Children's Research Hospital and the University of Pennsylvania designed proteolysis targeting chimeras (PROTACs) using dasatinib as an LCK ligand and phenyl-glutarimide as a cereblon-directing moiety.